- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Resolution Pharmaceuticals inks deals
Radiopharmaceutical developer Resolution Pharmaceuti-cals of Mississauga,Ontario, has entered into two R&D collaborations with Canadianinstitutes to develop new imaging agents. Both deals have thesupport of Canadian research agencies. In the first
Radiopharmaceutical developer Resolution Pharmaceuti-cals of Mississauga,Ontario, has entered into two R&D collaborations with Canadianinstitutes to develop new imaging agents. Both deals have thesupport of Canadian research agencies.
In the first deal, Resolution and the Alberta Peptide Institutewill receive up to $200,000 from the National Research Council'sIndustrial Research Assistance Program to investigate new radiopharmaceuticalsto image bacterial and fungal infections.
In the second deal, Resolution and the Ontario Cancer Centerreceived a $50,000 grant from the Medical Research Council ofCanada to research compounds to be used in functional medicalimaging that could also be used to aid disease treatment suchas chemotherapy.
Resolution Pharmaceuticals is a joint venture between Canadianradioisotope producer Nordion International and Allelix Biopharmaceuticals.The company's peptide-based radiopharmaceutical for imaging inflammatorydisease completed phase I clinical testing earlier this year (SCAN1/17/96).
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
